| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K/A: Costs Associated with Exit or Disposal Activities
On October 27, 2026, Artiva Biotherapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) with the Securities and Exchange Commission (the “SEC”) disclosing that the Company’s board of directors approved t... |
Loading...